[The correction action of Phosprenyl and Gamavit on the functional activity of mouse peritoneal macrophages in response to high doses of Staphylococcus aureus alpha-toxin].
The study of the functional activity of peritoneal macrophages of BALB/c mice at different stages of the toxic action caused by S. aureus alpha-toxin (ST) was carried out. The analysis of the dynamics of toxic reaction revealed the main critical points of triggering necrotic processes: the first hour and day 2. One hour after the injection of large doses of ST a sharp increase in the process of antigen binding with its subsequent sharp decrease. Simultaneously, a decrease in the activity of the lysosomal enzymes cathepsin D and acidic phosphatase was established, which was indicative of the destabilization of both lysosomal and cellular macrophage membranes. The increase of oxygen metabolism on day 2, together with the release of lysosomal proteases into the extracellular area, correlated with the maximum death rate of mice and served as the main index of the development of necrosis. The prophylactic and therapeutic use of the preparations Gamavit and Phosprenyl revealed their antitoxic activity and capacityfor stimulating the level of natural body resistance.
Zaĭtseva
L G
LG
Bekhalo
V A
VA
Vasil'ev
I K
IK
Godunov
R S
RS
Kireeva
I V
IV
Kozhevnikova
T N
TN
Nagurskaia
E V
EV
Narovlianskiĭ
A N
AN
Ozherelkov
S V
SV
Pronin
A V
AV
Sanin
A V
AV
D000135:Acid Phosphatase / Q000378:metabolism; D000276:Adjuvants, Immunologic / Q000008:administration & dosage / Q000494:pharmacology*; D000818:Animals; D001427:Bacterial Toxins / Q000008:administration & dosage / Q000276:immunology / Q000633:toxicity*; D002402:Cathepsin D / Q000378:metabolism; D004359:Drug Therapy, Combination; D007273:Injections, Intramuscular; D007279:Injections, Subcutaneous; D017737:Macrophages, Peritoneal / Q000187:drug effects* / Q000276:immunology / Q000378:metabolism; D051379:Mice; D008807:Mice, Inbred BALB C; D009336:Necrosis / Q000139:chemically induced / Q000517:prevention & control; D010101:Oxygen Consumption; D010587:Phagocytosis / Q000187:drug effects*; D011106:Polyisoprenyl Phosphates / Q000008:administration & dosage / Q000494:pharmacology*; D013203:Staphylococcal Infections / Q000188:drug therapy* / Q000503:physiopathology; D013211:Staphylococcus aureus / Q000201:enzymology*; D010738:Type C Phospholipases / Q000008:administration & dosage / Q000276:immunology / Q000633:toxicity*
D000276:Adjuvants, Immunologic; D001427:Bacterial Toxins; D011106:Polyisoprenyl Phosphates; C105485:phosprenyl; D000135:Acid Phosphatase; D010738:Type C Phospholipases; D002402:Cathepsin D